Cancer is a big health problem in Cuba and the rest of the world. Its morbidity and mortality rates, the numbers of people disabled by the disease and its effects on the quality of life of victims and their families all make it a great challenge for healthcare systems world wide.
This is why promotion and prevention strategies are part of many public health policies.
However this needs to be accompanied by technological development in the diagnosis and treatment of cancer related diseases.
One of the leading service packages offered at La Pradera International Health Centre is the Integrated Care and Treatment Program for cancer patients, calling on all the Cuban medications and immunotherapy treatment products that have over the past few decades helped to improve the quality of life and change the outlook of cancer sufferers.
Among the medications used is Nimotuzumab, for the treatment of adult and child patients with high grade malignant tumours of the central nervous system, such as multiform glioblastoma and anaplastic astrocitoma and advanced carbonomas of the head and neck, esophagus and pancreas. Cimavax-EGF and Racotumomab (Vaxira) are administered to patients with stage IIIB and IV non small cell lung cancer.
At our centre we work with an integral focus and personalize our service to each patient after a comprehensive individual assessment.
We have treated patients from many different parts of the world, from China to Canada, Venezuela, United States, Turkey and Serbia.
These treatments have been validated in various clinical trials. More than eight hundred papers relating to these therapies have been published by the Molecular Immunology Centre in Havana, Cuba.
The results published in these papers show that the therapies achieved reductions in relapses and an increase in the time between relapses. Quality of life improved and survival rates improved overall. Results evaluated as positive include both the low rate of toxicity reactions…both the low rate of toxicity reactions and adverse reactions related to the treatment, as well as survival rates translated to number of clinically healthy years lived.
We can say that we are on the right track to achieve our goal: that patients and their families learn to live life to the full despite their disease and that cancer becomes rather than a terminal condition, a non-transmittable chronic illness.